366 related articles for article (PubMed ID: 28634198)
21. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
Tapper EB; Parikh ND; Green PK; Berry K; Waljee AK; Moon AM; Ioannou GN
Clin Gastroenterol Hepatol; 2020 May; 18(5):1197-1206.e7. PubMed ID: 31589975
[TBL] [Abstract][Full Text] [Related]
22. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function.
Satapathy SK; Joglekar K; Molnar MZ; Ali B; Gonzalez HC; Vanatta JM; Eason JD; Nair SP
Liver Transpl; 2018 Aug; 24(8):1040-1049. PubMed ID: 29573131
[TBL] [Abstract][Full Text] [Related]
23. Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome.
Pandya P; Pant C; Taylor R; Oni O
J Investig Med; 2017 Apr; 65(4):765-771. PubMed ID: 28232517
[TBL] [Abstract][Full Text] [Related]
24. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy.
Berk DR; Mallory SB; Keeffe EB; Ahmed A
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):142-51. PubMed ID: 16919505
[TBL] [Abstract][Full Text] [Related]
25. Extrahepatic morbidity and mortality of chronic hepatitis C.
Negro F; Forton D; Craxì A; Sulkowski MS; Feld JJ; Manns MP
Gastroenterology; 2015 Nov; 149(6):1345-60. PubMed ID: 26319013
[TBL] [Abstract][Full Text] [Related]
26. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
28. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
29. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
[TBL] [Abstract][Full Text] [Related]
30. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
[TBL] [Abstract][Full Text] [Related]
31. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
32. [Extrahepatic manifestations of hepatitis C virus].
Cohen P
Presse Med; 2000 Feb; 29(4):209-14. PubMed ID: 10705902
[TBL] [Abstract][Full Text] [Related]
33. Dermatologic Manifestations of Chronic Hepatitis C Infection.
Sayiner M; Golabi P; Farhat F; Younossi ZM
Clin Liver Dis; 2017 Aug; 21(3):555-564. PubMed ID: 28689593
[TBL] [Abstract][Full Text] [Related]
34. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
[TBL] [Abstract][Full Text] [Related]
35. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.
Gragnani L; Cerretelli G; Lorini S; Steidl C; Giovannelli A; Monti M; Petraccia L; Sadalla S; Urraro T; Caini P; Xheka A; Simone A; Arena U; Matucci-Cerinic M; Vergani D; Laffi G; Zignego AL
Aliment Pharmacol Ther; 2018 Aug; 48(4):440-450. PubMed ID: 29952013
[TBL] [Abstract][Full Text] [Related]
36. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
37. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
38. [Extrahepatic manifestations of HCV infection].
Husa P
Vnitr Lek; 2016; 62(9 Suppl 2):18-22. PubMed ID: 27723989
[TBL] [Abstract][Full Text] [Related]
39. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.
Fernández I; Castellano G; de Salamanca RE; Colina F; Gómez de la Cámara A; Morán MJ; Muñoz R; Solís-Herruzo JA
Scand J Gastroenterol; 2003 Mar; 38(3):314-9. PubMed ID: 12737448
[TBL] [Abstract][Full Text] [Related]
40. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
Aliment Pharmacol Ther; 2019 Mar; 49(5):599-608. PubMed ID: 30650468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
